Víctor González-UribeHector Rodrigo Pastrana-AyalaLuis Hernandez-ZarateCarlos Andrés Gómez-NúñezMaria Julia Rendon-SalazarTamara Hernandez-HernandezRicardo Martínez-TenopalaZaira Selene Mojica-Gonzalez2026-03-222026-03-22202610.15586/aei.v54i2.1402https://doi.org/10.15586/aei.v54i2.1402https://andeanlibrary.org/handle/123456789/79887In this Latin American pediatric cohort, dupilumab achieved marked and sustained improvements in disease severity and quality of life, with a favorable safety profile. This real-world study addresses a regional evidence gap and supports dupilumab as an effective and well-tolerated treatment for moderate-to-severe pediatric AD.enDupilumabMedicineAtopic dermatitisSCORADQuality of life (healthcare)Observational studyAdverse effectDermatologyEczema Area and Severity IndexSeverity of illnessarticle